Conformis Appoints New Chief Financial Officer
Peter Traynor Brings Over 30 Years of Industry Experience
Bedford, Mass. – November 12, 2012 – Conformis, Inc., a privately held medical device company pioneering patient-specific orthopedic implants, announced today it has appointed 30-year business and financial management veteran Peter Traynor as the company’s Chief Financial Officer. The addition of Mr. Traynor bolsters the executive management team as the company continues to grow following the recent launch of its iTotal®G2 total knee replacement system.
Prior to joining Conformis, Mr. Traynor spent 10 years at Genzyme Corporation where he served as the Chief Accounting Officer and most recently as the Senior Vice President of Business Unit Finance. In this role he had responsibilities for SEC filings, controllership functions, and financial planning and forecasting for Genzyme’s eight global business units. He was also a member of the Global Operating Team and intimately involved in many of Genzyme’s successful acquisitions.
“We are very pleased to welcome Peter as our CFO at a time when the company is experiencing substantial growth,” said Philipp Lang, MD, CEO of Conformis. “We are at a very important and exciting point in the company’s history, and Peter’s past experience is very well suited to helping us achieve our goals of sustained growth and disciplined operating execution.”
Conformis recently announced the launch of its iTotal G2 total knee replacement system, the only personalized implant and instrument system designed to match a patient’s natural articulating shape. The iTotal allows Conformis to address the largest segment of the knee replacement market, currently a $6 billion dollar category. The company also recently moved their corporate offices to a substantially larger facility to support the recent and expected forward growth of the company.
“It’s very exciting to join a company that combines such an innovative and broad ranging technology with an exceptionally fast growing product offering,” said Mr. Traynor. “I look forward to joining a superb leadership team and working with them to support the continued growth of the company’s image-based technology platform.”
Mr. Traynor earned an M.S. in Finance from Bentley College Graduate School and a B.A. in Accounting from the University of Massachusetts. He is currently completing a G.M.A in International Relations from the Fletcher School of Law and Diplomacy at Tufts University.
For more information on Conformis visit www.conformis.com.
About Conformis, Inc.
Conformis, Inc. is a privately-held company that develops and commercializes medical devices for osteoarthritis treatment and joint damage. Its proprietary intellectual property includes more than 350 patents and patent applications in the areas of imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing, spanning knee, hip, shoulder, spine, and small joints. Conformis knee implants and instrumentation are designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery. All devices have been cleared by the US Food and Drug Administration for marketing in the US. In 2009, Conformis was named a winner of the Medical Design Excellence Awards for its iUni and iDuo resurfacing implants. In 2011, Conformis received a Medical Design Excellence Award and an American Technology Award for Innovation for the iTotal. Follow Conformis on Twitter at @Conformis and become a fan on Facebook.
New Clinical Study Finds Bilateral Knee Patients Prefer Conformis’ Fully Personalized Solution Over Competitive Off-the-Shelf Implants by a Factor of Over 10 to 1
Study included only patients with a fully personalized Conformis implant in one knee after previously receiving a competitive off-the-shelf implant
Conformis iTotal® CR Knee Replacement System Awarded “7A” Performance Rating from the U.K.’s Orthopaedic Data Evaluation Panel
Independently verified assessment of the performance of the fully personalized iTotal CR system over a 7-year period confirms that it meets the panel’s demanding standards